Eli Lilly (LLY) analyst forecast and price target
Analyst forecast
Consensus of 32 analyst ratings
Based on 12 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| RBC Capital | Maintained | Outperform | $1,500.00 | Oct 12, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $1,440.00 from $1,410.00 | Oct 8, 2026 |
| Morgan Stanley | Maintained | Overweight | $1,430.00 from $1,419.00 | Oct 7, 2026 |
| JP Morgan | Maintained | Overweight | $1,500.00 from $1,400.00 | Sep 28, 2026 |
| TD Cowen | Maintained | Buy | $1,250.00 | Sep 22, 2026 |
| Guggenheim | Maintained | Buy | $1,284.00 from $1,273.00 | Sep 18, 2026 |
| HSBC | Maintained | Reduce | $940.00 from $850.00 | Sep 10, 2026 |
| Truist Securities | Maintained | Buy | $1,376.00 from $1,370.00 | Aug 7, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $1,410.00 from $1,350.00 | Aug 6, 2026 |
| Wells Fargo | Maintained | Overweight | $1,330.00 from $1,280.00 | Aug 6, 2026 |
| Citigroup | Maintained | Buy | $1,600.00 from $1,500.00 | Jul 15, 2026 |
| Bernstein | Maintained | Outperform | $1,385.00 from $1,300.00 | Jul 14, 2026 |
| Guggenheim | Maintained | Buy | $1,273.00 from $1,235.00 | Jul 13, 2026 |
| UBS | Maintained | Buy | $1,425.00 from $1,250.00 | Jul 13, 2026 |
| B of A Securities | Maintained | Buy | $1,334.00 from $1,251.00 | Jul 10, 2026 |
| RBC Capital | Maintained | Outperform | $1,500.00 from $1,250.00 | Jul 8, 2026 |
| Morgan Stanley | Maintained | Overweight | $1,347.00 from $1,344.00 | Jul 8, 2026 |
| Truist Securities | Maintained | Buy | $1,370.00 from $1,281.00 | Jul 8, 2026 |
| JP Morgan | Maintained | Overweight | $1,400.00 from $1,300.00 | Jul 7, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $1,350.00 from $1,230.00 | Jul 6, 2026 |
Frequently asked questions
What is the price target for LLY stock?
The average 12-month analyst price target for Eli Lilly (LLY) is $1,371.67, with a high estimate of $1,600.00 and a low of $940.00, across 12 analysts.
Is LLY a buy, sell, or hold?
Analysts covering Eli Lilly currently average a Buy rating: 27 buy, 3 hold and 2 sell, from 32 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for LLY?
The average price target of $1,371.67 implies 15.91% upside from the last price of $1,183.35.
What is the latest analyst rating on LLY?
On Oct 12, 2026, RBC Capital maintained Eli Lilly at Outperform with a price target of $1,500.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.